XL-184+Abiraterone in Post-Chemo CRPC
A Dose Finding Clinical Trial of Cabozantinib (XL 184) Administered in Combination With Abiraterone in Castration Resistant Prostate Cancer
Sponsor: Dana-Farber Cancer Institute
This PHASE1 trial investigates Prostate Cancer and is currently completed. Dana-Farber Cancer Institute leads this study, which shows 10 recorded versions since 2012 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Sep 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Mar 2021 — Sep 2021 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Jan 2021 — Mar 2021 [monthly]
Active Not Recruiting PHASE1
▶ Show 5 earlier versions
-
Feb 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1
-
Mar 2019 — Feb 2020 [monthly]
Active Not Recruiting PHASE1
-
Jun 2018 — Mar 2019 [monthly]
Active Not Recruiting PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1
First recorded
Apr 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Dana-Farber Cancer Institute
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Boston, United States